Clinical Trial Update: Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluates pembrolizumab as adjuvant therapy in patients with early-stage triple-negative breast cancer who have residual disease after neoadj…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma | Phase 3 | Status: NOT_YET_RECRUITING